Non-invasive Spinal Stimulation for Gait in Genetic Spasticity
NCT07930481, Not applicable, Enrolling by invitation, University of Washington
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Non-invasive Spinal Stimulation for Gait in Genetic Spasticity | ClinicalTrials.gov |
| NCT number | NCT07930481 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 4 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Washington | ClinicalTrials.gov |
| Conditions | Hereditary Spastic Paraplegias, Spinocerebellar Ataxia, Spastic Ataxia | ClinicalTrials.gov |
| Interventions | Transcutaneous spinal cord stimulation, Sham transcutaneous spinal cord stimulation | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Spastic Paraplegia Rating Scale (SPRS) | This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16. | This is a 13-point clinical scale that assesses the severity of symptoms attributable to hereditary spastic paraplegia. Scores range from 0 (no impairment) to 52 (severe impairment). | ClinicalTrials.gov |
| Secondary | Lower extremity dynamometry | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a qantitative assessment of force generated by the muscles of the lower extremity, measured in Newtons. | ClinicalTrials.gov |
| Secondary | 25-foot timed walk test | This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16. | This is a quantitative assessment of mobility and leg function that measures the time it takes an individual to safely and quickly walk a distance of 25 feet. | ClinicalTrials.gov |
| Secondary | 2-minute walk test | This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16. | This is a clinical functional assessment that measures the maximum distance a person can walk on a flat, hard surface in two minutes. Assesses self-paced walking ability, functional endurance, and aerobic capacity. | ClinicalTrials.gov |
| Secondary | Hmax/Mmax ratio | This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16. | This is an electrophysiological quantification of spasticity. | ClinicalTrials.gov |
| Secondary | Mini-Balance Evaluation Systems Test (Mini-BEST) | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a clinical assessment of balance performed by a physical therapist. Scores range from 0 (severe balance impairment) to 28 (no balance impairment). | ClinicalTrials.gov |
| Secondary | Patient Global Impression of Change (PGIC) | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a short, patient-reported outcome measure used in clinical trials and medical practice to evaluate how much a patient's condition has changed since the start of treatment. Scores range from 1 (very much improved) to 7 (very much worsened). | ClinicalTrials.gov |
| Secondary | Clinician Global Assessment of Change (CGIC). | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a clinician-reported outcome measure used in clinical trials and medical practice to evaluate how much a patient's condition has changed since the start of treatment. Scores range from 1 (very much improved) to 7 (very much worsened). | ClinicalTrials.gov |
| Secondary | Neuropathic Bladder Symptom Score (NBSS) | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a validated, patient-reported outcome measure, designed to evaluate urinary symptoms, complications, and quality of life in individuals with neurogenic lower urinary tract dysfunction. Scores range from 0 (no symptoms) to 74 (severe symptoms). | ClinicalTrials.gov |
| Secondary | Neuropathic Bowel Dysfunction Scale (NBDS) | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a 10-item clinical questionnaire used to evaluate bowel symptoms, track treatment effectiveness, and measure quality of life in patients with neurogenic bowel conditions. Scores range from 0 (no symptoms) to 47 (severe symptoms). | ClinicalTrials.gov |
| Secondary | Neuropathic Pain Symptom Inventory (NPSI) | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is a self-administered, 12-item clinical questionnaire designed to evaluate and quantify the specific symptoms of peripheral and central neuropathic pain. Scores range from 0 (no pain) to 100 (worst pain imaginable). | ClinicalTrials.gov |
| Secondary | Patient Reported Outcome Measurement Information Systems (PROMIS) Item Bank v1.0 - Pain Interference - Short Form 8a | This assessment will be performed at baseline, and again at weeks 4, 8, 12, and 16. | This is an 8-point patient-reported questionnaire that measures how much pain hinders a person's physical, mental, emotional, social, and recreational activities over the past 7 days. Scores range from 8 (not at all) to 40 (very much). | ClinicalTrials.gov |
| Secondary | Modified Ashworth Scale (MAS) | This assessment will be performed at baseline, and again at weeks 2, 4, 8, 10, 12, and 16. | This is a clinical assessment used to quantify muscle tone and resistance to passive movement in neurological conditions. Raters will assess spasticity with hip flexion, hip extension, hip adduction, hip internal rotation, hip external rotation, knee flexion, knee extension, and plantarflexion. For each joint tested, scores range form 0 (no spasticity) to 4 (severe spasticity). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 9
The papers the trial lists on ClinicalTrials.gov.
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.